Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALACE-1: Pre-Operative Pembrolizumab in Esophageal Squamous Cell Carcinoma
NCT03792347Phase 1Completed
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03792347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792347.